# US 2015/0148432 A1 · Assessing susceptibility to vascular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148432 A1
- Document ID: US20150148432A1
- Status: Published application
- Kind: A1
- Application number: 14/331,173
- Filed: 2014-07-14
- Published: 2015-05-28
- Earliest claimed: 2007-11-01
- Assignees: University of Iowa Research Foundation
- Applicants: University of Iowa Research Foundation
- Inventors: Gregory S. Hageman
- Web page: https://patentgrep.com/patent/US20150148432A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 38/1709: {from mammals}
- A61P 27/02: Ophthalmic agents
- C07K 16/40: against enzymes
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/172: Haplotypes
- Y10T 436/147777: Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases.

## Claims

### Claim 1

A method of determining an individual's risk of abdominal aortic aneurysm(AAA) or a AAA-associated vascular disorder comprising screening the genome of the individual for the presence or absence of a genetic profile characterized by at least one polymorphism selected from Table 1A and/or Table 2A associated with increased risk for or protection against AAA, wherein the presence of a said genetic profile is indicative of the individual's relative risk of AAA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the risk of AAA is determined.

### Claim 3 (depends on 1)

The method of claim 1, wherein the genetic profile comprises at least one polymorphism selected from Table 1A.

### Claim at position 4

4-21. (canceled)

### Claim 22

A method for treating AAA, the method comprising (i) identifying an individual as having a genetic profile characterized by polymorphisms indicative of risk for developing AAA, wherein the genetic profile comprises at least one polymorphism selected from Table 1A or Table 2A, and (ii) treating the individual.

### Claim 23 (depends on 22)

The method of claim 22, wherein the genetic profile comprises at least one polymorphism selected from Table 1A.

### Claim 24

A kit for determining an individual's risk of abdominal aortic aneurysm (AAA) or an AAA-associated vascular disorder in a human subject, the kit comprising reagents for screening, in a sample from the subject, for the presence or absence of a genetic profile in the genome of the subject characterized by at least one polymorphism selected from Table 1A and/or Table 2A associated with increased risk for or protection against AAA, wherein the presence of a said genetic profile is indicative of the individual's relative risk of AAA.
